“This is a very good sign that we make an antibody that can stop the virus from replicating,” Moderna Chief Executive Officer Stephane Bancel said in an interview. The data “couldn’t have been better,” he said.
By contrast, the mRNA technology being used by Moderna and several others relies on the body’s own cells to produce viral proteins. Once injected into the body, the RNA slips into human cells and tells them to make virus-like proteins, in this case the “spike” protein on the surface of the coronavirus. If the vaccine works, those proteins then trigger the body to generate protective antibodies.
While the technology is new and hasn’t been used in an approved vaccine before, it allows researchers to move fast into trials. Moderna started working on its Covid-19 vaccine as soon as Chinese scientists put out the gene sequence for the virus in January. By late February, Moderna’s scientists had already delivered the first batch of candidate vaccines to researchers at the U.S. National Institutes of Health. In mid-March, the first healthy volunteer received a dose in the government-sponsored safety trial.
The coronavirus is a gift for the emerging one-shot genetic solutions field. Vaccines are a perfect testing ground for the technology because the virus demands a quick effective solution where one or two doses give immunity.Click HERE to subscribe to Fuller Treacy Money Back to top